中国原发性肝癌临床分期预测肝癌肝移植预后的临床研究

目的评价“中国原发性肝癌临床分期”对肝癌肝移植疗效的预测价值。方法对1993年4月至2003年1月我科59例采用肝移植治疗的肝癌病人临床资料进行回顾性分析,按中国原发性肝癌临床分期原则进行分期,比较各期间肝癌肝移植疗效。结果Ⅰb、Ⅱa、Ⅱb、Ⅲa和Ⅲb期移植术后1年生存率分别为83·33%、66·67%、50·00%、35·71%和16·67%,各期间术后累计生存率有统计学差异(P<0·01);Ⅰb~Ⅱb和Ⅲa~Ⅲb期移植术后1年生存率分别为66·67%和25·00%,2年生存率分别为45·71%和25·00%,两组间术后累计生存率有统计学差异(P<0·05)。结论中国原发性肝癌临床分期适用于肝癌肝移植术前分期。     

Diagrammatic recording of head and neck tumours1

The increasing demands of clinical audit have resulted in the need for accurate data collection. The use of tumour maps allows standardization of the records of patients with head and neck cancer, which facilitates collation of data in multicentre studies and makes interdepartmental comparisons more meaningful. The aim of this study was to develop an improved standard set of tumour maps for recording the stage of head and neck tumours. A review of the existing tumour diagrams was performed to identify those anatomical areas that are not adequately represented or where ambiguity exists. The areas where improvements could be made were identified as: (1) the anterior commissure of the larynx; (2) axial and sagittal views of the larynx; (3) the pyriform fossa and cervical oesophagus; (4) the oropharynx and vallecula; (5) the nasal cavity and paranasal sinuses; and (6) cervical nodal involvement. A new set of tumour maps is presented in an attempt to correct some of the limitations of the existing diagrams.     

食管腺癌淋巴结转移与肿瘤侵及食管壁深度的关系

目的 对腺癌侵及食管壁深度与淋巴结转移的关系以及淋巴结转移对预后的影响进行分析研究.方法 澳大利亚弗林德斯大学医学中心自1985年～2003年,手术治疗食管腺癌121例.其中男101例,女20例.年龄36～80岁,平均62岁.本组手术切除率为96.7%（117/121例）.手术清扫淋巴结的数目每例为2～30个,平均8个.无淋巴结转移59例（48.8%）、有淋巴结转移62例（51.2%）.本组病例全部得到随访.结果 当肿瘤位于黏膜层或黏膜下层（T1）时,淋巴结转移的发生率为22.2%（10/45例）、平均淋巴结转移的个数为0.3个、＞4个淋巴结转移的比例为0（0/45例）;当肿瘤侵及食管周围组织（T4）时,淋巴结转移的发生率为85.7%（6/7例）、平均淋巴结转移的个数为5.1个、＞4个淋巴结转移的比例为71.4%（5/7例）,P＜0.05.无淋巴结转移组的5年生存率为52.9%、1～4个淋巴结转移组的5年生存率为11.5%、＞4个淋巴结转移组的5年生存率为0,P＜0.01.结论 肿瘤对食管壁侵及深度和淋巴结转移的发生率及淋巴结转移的数量之间存在正相关性.随着肿瘤对食管壁侵及深度的增加,淋巴结转移的发生率、平均淋巴结转移的数量和＞4个淋巴结转移的比例均增加.有无淋巴结转移和淋巴结转移的数量是影响远期生存率的一个重要因素.     

Association between age and clinical characteristics of renal cell carcinoma in adult patients

AIM: To study the association between age and clinical characteristics of renal cell carcinoma in adult patients. METHODS: Three hundred and ten patients with renal cell carcinoma were classified into three groups: or=60 years group. The clinical characteristics of the three groups were compared to define the association. RESULTS: The male/female ratio was 1.3/1, 2.0/1, 3.3/1 in the three groups, respectively, and a significant difference appeared when comparing the or=60 years group (P=0.010). The respective percentage of incidental renal cell carcinoma was 27.9%, 43.2%, 31.2%, and it was significantly higher in the 41-59 years group than the >or=60 years group (P=0.047). The incidence of poorly differentiated renal cell carcinoma decreased with age increasing (11.6% vs 5.2% vs 2.7%), and there was significant difference between the or=60 years group (P=0.038). In the 相似文献   

Staging-laparoscopy

Summary. The so-called extended diagnostic laparoscopy (EDL) facilitates the comprehensive exploration of the abdominal cavity, thus improving the precision of the pretherapeutic tumor staging in gastrointestinal malignancies. EDL comprises visual inspection with a specific preparation of all relevant sites, laparoscopic sonography and retrieval of samples for biopsy and cytology. Additional relevant therapeutic information was obtained through EDL in 40.5 % of gastric cancer patients. EDL could be of similar importance for diagnosing esophageal, hepatobiliary and pancreatic malignancies.      

原发性肝癌的分期、根治切除标准及预后指标

论述了原发性肝癌的分期方案，根治切除标准及预后指标。三者的研究进展及相互间的关系。肝癌临床分期尚没有统一的实用方案，TNM分期随着不断修订，得到了一定的认可和推广。我国1999年修订的方案大致与TNM分期相对应，目前也没有通用的肝癌切除根治标准，临床上通常分为根治性切除与姑息性切除两类，比较笼统，在细胞病理学的基础上可分为病理根治性，临床根治性和姑息性切除三类，多因素分析表明，影响肝癌总体预后的因素主要是肿瘤分期，病理类型，治疗措施。肿瘤生物学特性以及并发症，而影响手术后复发和转移的因素主要是手术切除程度和病理特征，临床分期是选择治疗方案的基础。预后分析则是验证肝癌的分期和根治切除标准是否合理的手段；肝癌的准确分期，根治切除的判断及预后水平的提高均有赖于分子生物学技术的进步。     

The relationship of proliferating cell density at the invasive tumour front with prognostic and risk factors in human oral squamous cell carcinoma

BACKGROUND: We hypothesise that the density of proliferating cells at the invasive tumour front (ITF) has a positive relationship with prognostic and risk factors in human oral squamous cell carcinoma (SCC). METHODS: Tissues from 47 human oral SCC specimens were collected and stained with a monoclonal antibody directed against the Ki-67 antigen using a horseradish peroxidase based two-step immunostaining method. Counting was performed on two parallel sections at the ITF using an image analyser. The Ki-67 labelling index (LI) was determined by measuring the number of nuclei/mm(2) of epithelium. RESULTS: Our results show that the density of proliferating cells is related to clinical staging, with advanced stage of disease having a significantly higher Ki-67 LI compared with early stage of disease (2111 +/- 905 vs. 1908 +/- 913; P = 0.03). Importantly, this study shows that tumours that have metastasised have a significantly higher Ki-67 LI than tumours where distant metastasis was not detected (3257 +/- 650 vs. 1966 +/- 881; P < 0.0001). CONCLUSIONS: Cell proliferation, as measured by the Ki-67 LI at the ITF, has a positive relationship with clinical staging, tumour thickness, smoking status of the patient and alcohol consumption. Further, we suggest that a multicenter study with a large cohort of patients is indicated to fully elucidate whether cell proliferation at the ITF is directly related to patient survival.     

Developments in treatment of primary irresectable rectal cancer

Abstract The treatment options for primary irresectable rectal cancers are discussed. Assessment of tumour stage is the first step for an appropriate choice of treatment. Following a diagnosis of rectal cancer, a vast array of diagnostic procedures is available to determine its stage, and thereby its best treatment options. From the many (new) diagnostic options the merits and drawbacks are discussed. If a diagnosis of irresectability is made, further treatment options should include radiotherapy in most cases, some aspects of timing and application, i.e. intra-operative treatment are discussed. Chemotherapy options are manifold, the results are discussed and some new options are explored.     

外科治疗III_A期N_2非小细胞肺癌的预后分析及临床意义

目的探讨影响IIIA期N2非小细胞肺癌(NSCLC)预后的因素,并分析经手术治疗不同亚组病人的生存率差异。方法分析1997年1月至2000年1月146例手术治疗的IIIA期N2NSCLC病人的可能影响预后因素:病理类型、肿瘤位置、肿瘤大小、手术方式、临床N2情况,N2转移组数及个数、术后辅助治疗等,并用Kaplan-Meier曲线及Logrank检验生存率差异,Cox单因素、多因素分析各因素对生存率的影响。结果IIIA期N2NSCLC病人的3年和5年生存率分别为19.86%和14.56%。单因素分析示肿瘤位置、临床N2情况、N2转移组数及个数是影响生存率的因素;多因素分析示肿瘤大小、临床N2情况,N2转移组数和肿瘤位置影响预后。右肺下叶肿瘤单组或单个N2转移,预后最好。结论纵隔N2转移淋巴结的大小、个数和组数是影响术后生存率主要因素。手术前未发现N2转移(mN2),有1组N2转移(N2L1),N2转移数少于4个者手术治疗效果好。右肺下叶肿瘤发生单组N2淋巴结转移预后好。     

Treatment and prognostic factors in patients with hepatocellular carcinoma.

INTRODUCTION: Hepatocellular carcinoma is a leading cause of death from cancer worldwide. Survival of patients depends on tumor extension and liver function, but yet there is no consensual prognostic model. AIMS: To evaluate the influence on survival of pretreatment parameters (clinico-laboratorial, liver function, tumor extension, Okuda and Cancer of the Liver Italian program (CLIP) staging) and treatment modalities. METHODS: We retrospectively analyzed 207 patients, diagnosed between 1993 and 2003. The initial treatment was: surgery--six patients; radiofrequency ablation--21; percutaneous ethanol injection--29; transarterial chemoembolization--49; tamoxifen--49; supportive care alone--53. Factors determining survival were assessed by Kaplan-Meier method and Cox regression models. RESULTS: Median survival was 24 months. In univariate analysis, Child-Pugh classification and Model for end-stage liver disease (MELD) score, portal vein thrombosis (PVT), tumor size, number of lesions, Okuda and CLIP scores were all associated with prognosis (P < 0.001). Alpha-fetoprotein levels were not predictive of survival. Independent predictors of survival were ascites, bilirubin, PVT and therapeutic modalities (P < 0.001). In early stage hepatocellular carcinoma (HCC), survival was similar for both percutaneous ablation modalities, either radiofrequency or ethanol injection (P = NS). In advanced HCC, survival was better in patients receiving tamoxifen than supportive care alone (P < 0.001). CONCLUSION: This study reinforces the importance of baseline liver function (Child-Pugh classification and MELD score) in the survival of patients with HCC, although staging systems allowed the stratification of patients in different prognostic groups. Ascites, bilirubin and PVT were independent pretreatment predictors of survival. All treatments influenced the patient's outcome, whether in early or advanced stages.